Medicines & Healthcare products Regulatory Agency

MHRA Regulating Medicines and Medical Devices

MHRA Freedom of Information Act (FOIA) request Disclosure Log index

This document contains reference details for all FOIA requests which have been answered in full or in part, or for which the agency held no information.

It is a fully searchable PDF which will produce a list of all requests containing the chosen search term.

If you wish to see the original request and subsequent agency reply, please send an email headed “Disclosure Log request” to:

FOI_policy@mhra.gsi.gov.uk

As long as it is headed correctly it will not be treated as a new FOIA request, and will be answered within 3 working days. The identity of the original requester will be redacted.

Updated: [1 MAR 2018]

Case number (FOI, SAR, EIR)	Subject	Date of Reply	Outcome
FOI 17/436	A listing of Yellow Card Reports categorised as Serious and submitted for the HPV vaccination from 1st July 2017 to 30th September 2017	30/10/2017	Disclosed in full
FOI 17/437	PAR request for Amoxicillin PL06453/0017-8 1988 and 2012	11/10/2017	Disclosed in full
FOI 17/438	Copy of archived document - "Committee on Safety of Medicines: Sub-Committee on Toxicity, Clinical Trials and Therapeutic Efficacy; meetings 1-11 (1974)	01/11/2017	Not held
FOI 17/439	Copies of attachments that formed part of the emails provided for FOI 17/326	10/10/2017	Disclosed in part
FOI 17/440	Number of current ongoing clinical trials in the UK, with UK **only** as the study site/location	02/11/2017	Disclosed in part
FOI 17/445	Versatis medicated plaster - Risk Management Plan	13/11/2017	Disclosed in part
FOI 17/448	RMP PL 21844/0026 STRAGEN UK Moonia tablets & PL 35507/0188 Lupin Europe Desogestrel Tablets	26/10/2017	Disclosed in part
FOI 17/451	Vaccine death statistics request	09/11/2017	Disclosed in full
FOI 17/452	Interactions of St John's wort - Hypericum perforatum	06/11/2017	Disclosed in full
FOI 17/453	PAR for Ketofall 0.25 mg/ml eye drops, solution in single-dose	19/10/2017	Disclosed in part
FOI 17/455	Supply latest Drug Analysis Report for the HPV vaccines, Cervarix, Gardasil, unbranded and Gardasil 9.	10/11/2017	Disclosed in full
FOI 17/456	DAP for various vaccines including MMR and Gardasil	10/11/2017	Disclosed in full
FOI 17/458	Information used to assign investigation levels for reports received about medical devices.	10/11/2017	Disclosed in part
FOI 17/459	PAR Teriparatide	19/10/2017	Disclosed in full
FOI 17/460	Supply the names of 12 products and the 10 vaccines removed from UK list	14/11/2017	Disclosed in full

FOI 17/462	List of accepted CPRD applications	27/10/2017	Disclosed in full
FOI 17/463	A copy of the Norgine pharmacovigilance inspection report	19/10/2017	Disclosed in part
FOI 17/465	Dysport and Azzalure	14/11/2017	Disclosed in full
FOI 17/466	Flu vaccination for Children	20/10/2017	Disclosed in full
FOI 17/467	Clinical trials in CPRD	20/11/2017	Disclosed in part
FOI 17/468	Request & confirmation of TVT mesh being surgically misplaced	17/11/2017	Disclosed in full
FOI 17/469	CDB & World Health Organisation	16/11/2017	Disclosed in full
FOI 17/470	Video Conferencing Hardware and software	16/11/2017	Disclosed in full
FOI 17/471	Inspection reports for Mawdsley Brookes and Company Ltd & Polar Speed Distribution Ltd	17/11/2017	Disclosed in part
FOI 17/472	Devices of counterfeit and unlicensed medicines that have been seized in the UK by the MHRA between June 2015 - June 2017	17/11/2017	Disclosed in part
FOI 17/473	FOI Request for disclosure log on rejected requests	21/11/2017	Disclosed in part
FOI 17/474	Thimerosal In Vaccines After Manufacturing	16/11/2017	Disclosed in full
FOI 17/475	I request that MHRA, and, GSK, provide me with copies of all Patient Information Leaflets (PIL) for “Do Do Chesteze” since 1927	08/11/2017	Disclosed in full
FOI 17/476	Inspection report	17/11/2017	Disclosed in full
FOI 17/477	Safety of vaccination program for toddlers / children in UK	22/11/2017	Disclosed in full
FOI 17/478	ADR reports for Post viral fatigue syndrome, Chronic fatigue syndrome, Anxiety that have subsequently updated the card to report Postural Orthostatic Tachycardia Syndrome	27/11/2017	Disclosed in full

FOI 17/479	Research for 4head stick licence information	08/11/2017	Not held
FOI 17/480	Clinical and Non-Clinical data for a clinical trial approved by the MHRA	22/11/2017	Disclosed in part
FOI 17/482	Request for number and names of ant idepressants with reported adverse effect	01/11/2017	Disclosed in full
FOI 17/483	Unlicened medicines or Named Patient Supply	24/11/2017	Not held
FOI 17/488	All published Patient Information Leaflets included in boxes of Paroxetine in UK between 1988-2017. All the clinical trial data used by the government secretariat in giving Paroxetine a licensed indication for treatment of depression and OCD	30/11/2017	Disclosed in full
FOI 17/490	Disclose copies of two previous FOI disclosures by the MHRA relating to Valproate. Also if MHRA was alerted to a pattern of claims against NHS relating to Valproate and any memorandum of understanding between MHRA and NHSLA.	04/12/2017	Disclosed in part
FOI 17/491	Complete copy of the following FOI reports under MHRA FOI/DPA Disclosure log , 16/589, 16/591, 16/603 ,16/656 , 17/019, 17/055	01/12/2017	Disclosed in part
FOI 17/493	Request for PAR/documentation that states Eldepryl is the originator/reference product for selegiline in the UK.	29/11/2017	Disclosed in full
FOI 17/494	All emails, correspondence and minutes in relation to the decision by MSP and former Health Secretary Alex Neil to suspend the use of mesh and mesh tapes in Scotland in June 2014	05/12/2017	Disclosed in part
FOI 17/495	Can you advise if anyone has been granted a licence for Nitisinone in the UK or Europe in the last few weeks?	08/11/2017	Disclosed in full
FOI 17/496	ADR device called Nellix which is used in patients undergoing surgery/repair for an Abdominal Aortic Aneurysm (AAA).	29/11/2017	Disclosed in part
FOI 17/498	Inspection report Patheon UK	29/11/2017	Disclosed in part
FOI 17/499	Will this drug Mvasi (generic version of bevacizumab) be licensed? Is a committee looking at approving it?	10/11/2017	Disclosed in part
FOI 17/500	Clinical and non-clinical data that supported the initial application for Efcortesol 100 mg/mL Injection, PL 20072/0229. The data we would specifically want would relate to the following: Phase 2/3 efficacy and safety clinical studies; Any	06/12/2017	Disclosed in full
FOI 17/501	pressurised inhalation - 1) The Day 70 clinical assessment report 2) The Day 120 clinical assessment report 3) The two pharmacodynamic studies (identified as pharmacodynamic study #1 and #2 in the Public Assessment Report) submitted in support of this application.	28/11/2017	Disclosed in part

FOI 17/502	Request the minutes of a day-long workshop held at the MHRA in March 2011 with respect to the number of adverse events reported following insertion of synthetic tapes for female SUI.	01/12/2017	Disclosed in full
FOI 17/503	Copy of study to see if blood and hepatitis were cross-contaminated via a Ped-O-Jet injector.	11/12/2017	Not held
FOI 17/504	Information on private companies used to undertake PR, Social Media comms, External Stakeholder comms and internal stakeholder comms	06/12/2017	Disclosed in full
FOI 17/507	I would now like the original report with out any of the information that has been retracted that was supposed to of been released on the 16th October 2017.	14/12/2017	Disclosed in part
FOI 17/508	Which evidence and documents where used in compiling the ewg report on primodos published yesterday?	15/12/2017	Disclosed in full
FOI 17/513	Domain suspension requests	15/12/2017	Disclosed in part
FOI 17/515	Public assessment reports for Cefradine 250mg(500mg) Capsules17/11/2017	24/11/2017	Not held
FOI 17/516	Licensing status of 8% glycerin based minoxidil	28/11/2017	Not held
FOI 17/518	Information about internet webpages accessed by staff: 1. A list of the 500 most accessed websites over the past 12 months (December 2016 to December 2017) 2. The URL of the website and number of times it has been	19/12/2017	Disclosed in part
FOI 17/519	Public Assessment Report for the authorised medicinal product-SINEPIN Capsules 25 mg, PL PL 23138/0002	28/11/2017	Not held
FOI 17/520	Information relating to the seizure of drugs sent to addresses in Northern Ireland	28/12/2017	Disclosed in full
FOI 17/522	Provide -Public Assessment Report for “Triamcinolone Acetonide 0.1% Oroplast”;. Reference Product to be used for RLD & Bio-studies; Bio-study/clinical trial data	28/11/2017	Not held
FOI 17/525	Clinical and Non-clinical Reviews for Glycopyrronium Bromide 1mg/2mg Tablets [PL 20117/0094-0095]	12/01/2018	Disclosed in part
FOI 17/526	Risk management plans (RMP) for following listed drug product: 1) ZOPICLONE TABLETS 7.5 mg; PL 19156/0076; JUBILANT PHARMACEUTICALS NV 2) ZOPICLONE TABLETS 3.75 MG; PL 20117/0268;	06/12/2017	Disclosed in part

FOI 17/527	We understand that a European trial for the use of such scaffolding in breast reconstruction surgery ran from July 2011 to February 2015. The manufacturer of the SeriScaffold at the time was Allergan. Can you please confirm whether use of the scaffolding outside of this centre was not licensed and approved by the MRHA?	04/12/2017	Disclosed in full
FOI 17/528	PAR for Kenolog Oroplast (MAH: Bristol Myers Squibb)	05/12/2017	Disclosed in full
FOI 17/529	ADR data for Xeralto and Pradaxa and details	30/11/2017	Disclosed in full
FOI 17/530	What agreements the organisation has around General Data Protection Regulation (GDPR) compliance services	05/12/2017	Not held
FOI 17/532	Request information on MHRA annual statement of comprehensive income for the year ended on 31 March 2017	14/12/2017	Disclosed in full
FOI 17/533	Why is Dogmatil discontinued in Britain in 2007 ??	21/12/2017	Disclosed in full
FOI 17/534	Request legal basis of the authorisation & related public assessment report for Ascorbic Acid Injection BPC 500mg/5ml	08/01/2018	Disclosed in full
FOI 17/535	What is your total expenditure per annum on print and related activity? Details of any current in house print function and value of print produced 'in house' vs. outsourced.	18/12/2017	Disclosed in full
FOI 17/536	Provide any further information (e.g. a summary report), regarding an MHRA inspection at Bradford Royal Infirmary in 2015. I understand there were critical findings (which were not unexpected by the hospital) and further details have been	02/01/2018	Disclosed in part
FOI 17/538	The number of applications made to MHRA during the period 1 January 2007 to October 2017 for a parellel import licences	04/01/2018	Disclosed in part
FOI 17/539	You have a policy of making domain suspension requests to Nominet.[1] Can you send me: The policy document governing your domain suspension requests policy; Any template for notifications made to Nominet for domain suspension requests;	05/01/2018	Disclosed in part
FOI 17/540	Has an application for a European (decentralized) or national procedure has been filed with the MHRA for a medicinal product containing sildenafil in a pharmaceutical form to be topically applied.	08/01/2018	Disclosed in part
FOI 17/541	Current MHRA view on the Pfizer/Hospira facility in Croydon? • Unit 1, Stafford Cross Business Park, Croydon, CR0 4TU	05/01/2018	Disclosed in part
FOI 17/543	I have some questions in relation to the Indian producer, Lupin, who manufactures and BE tests products for Western pharmaceutical companies. I'm asking for Lupin India because the company has recently received a FDA Warning. Is this	12/01/2018	Disclosed in part

FOI 17/544	I'm writing regarding an Indian pharmaceutical producer named Lupin, which was issued a warning letter last month by the U.S. Food and Drug Administration for failing manufacturing compliance standards at one of its facilities in India: - Is the MHRA planning to take any action regarding the Lupin facility mentioned in the warning letter? Does the MHRA plan to ask for a recall of products made at this Lupin facility?	12/01/2018	Disclosed in full
FOI 17/545	Could I request a list of API sites Inspected by MHRA for Omeprazole in the last 3 years?	15/01/2018	Disclosed in full
FOI 17/547	If you could supply the list of refused requests and reasons from January 2015 onwards, that would be much appreciated. Would this include a list of requests "Disclosed in Part"? If I could get the reasons for exemption for those 'disclosed in part' as well	15/01/2018	Disclosed in full
FOI 17/548	I would like to request closed MHRA inspection audits reports with major and/or critical findings – of the last 12 months	17/01/2018	Disclosed in part
FOI 17/549	Release information regarding Clinical and non-clinical data for MK-0952	05/01/2018	Not held
FOI 17/550	Please provide copies of all correspondence sent by Ian Hudson between October 30, 2017, and November 17, 2017,	19/01/2018	Disclosed in part
FOI 17/551	RobiCold Sinus Relief 200mg, 30mg Tablets (Distributed By) Pfizer Consumer Healthcare granted by the MHRA - was it granted additional data protection in terms of when a generic application can be submitted. Can you also confirm this product can be used as a reference product in a biostudy.	05/01/2017	Disclosed in full
FOI 17/553	Please provide the date when the Committee On Human Medicines "final decision" will be made and where the final set of Minutes following the "final decision" may be viewed.	22/12/2017	Disclosed in full
FOI 17/554	Can you advise if anyone has been granted a licence for Nitisinone in the UK or Europe in the last few weeks?	08/01/2018	Disclosed in full
FOI 17/555	UNICEF has via the Rapid Alert System been informed that a GMP non-compliance statement has been issued on The Acme Laboratories Ltd., Bangladesh. I would be appreciated if MHRA could share the GMP inspection report with UNICEF as	12/01/2018	Disclosed in part
FOI 17/556	Please tell me why MHRA are not stipulating to companies who manufacture medicines that in the "Product Information Leaflets" / "PILs" that are put in packs of the medicines, to also say in companies' Product Information Leaflets: "Ask your GP to refer you to a Specialist Hospitals (not nonspecialist hospitals) if you suffer from rare side effects	09/01/2018	Disclosed in full
FOI 17/557	Documentation for the product Neupogen which was approved via DCP for which UK acts as Reference Member State and for which the procedure number is UK/H/0019/01-09/DC. We request a copy of the most recent Risk Management Plan (RMP) for this procedure.	10/01/2018	Disclosed in part

FOI 17/560	Data exclusivity for RobiCold Sinus Relief 200 mg, 30 mg Tablets PL 00165/0391	04/01/2018	Disclosed in full
FOI 17/561	The number of reports received by the MHRA of adverse sexual effects caused by SSRIs.	15/01/2018	Disclosed in full
FOI 17/563	Inspection report for Macleods Pharmaceuticals Limited, Baddi	30/01/2017	Disclosed in part
FOI 18/003	Azzalure/Dysport	25/01/2018	Disclosed in full
FOI 18/009	Request report (Petersen J.. Wise, L. Prescribing trends of bisphosphonates in general practice, UK 1995-2008. Pharmacoepidemiology and Drug Safety. '19. 'S315).	11/01/2018	Disclosed in full